Episoder
-
For more than 35 years, Gilead has been a leading innovator in the field of HIV, driving advances in treatment, prevention and cure research. These advances have transformed the outlook for people affected by HIV worldwide. In parallel, Gilead’s focus on catalytic collaborations at the global, national and local levels have helped to address the unmet needs of a wide range of individuals and communities.
Jared Baeten is a physician, epidemiologist and head of R&D at Gilead Sciences who has spent decades working in partnership with collaborators around the world to help overcome the HIV epidemic. In this episode he discusses:
The current landscape of HIV research
Optionality and choice in HIV treatment and care
Beyond the lab: education, access and barriers to care
Achieving the collective vision of ending the HIV epidemic
This podcast was created by our partner Gilead Sciences and produced by New Scientist CoLab.
Hosted on Acast. See acast.com/privacy for more information.
Learn more about your ad choices. Visit megaphone.fm/adchoices -
Artificial Intelligence is revolutionising manufacturing and transforming the industrial world. From solving challenges thought unsolvable, to improving efficiency and sustainability, AI is a new type of industrial revolution that reduces energy usage and waste. And at its helm is global technology company Siemens.
Pina Schlombs is an expert on sustainability and AI at Siemens and in this episode she discusses:
A robot gripper showcasing the power of industrial AI to solve complex engineering problems in a way that reduces their environmental impact.
How industrial copilots are transforming the way we programme machines and generate product designs.
How the logistics and carbon footprints of supply routes are being optimised with industrial AI.
And why she’s optimistic this technology will help us achieve our ambitious net-zero goals.
This is a New Scientist CoLab production, sponsored by Siemens.
Your host is Justin Mullins. Find out more at newscientist.com/podcasts
Hosted on Acast. See acast.com/privacy for more information.
Learn more about your ad choices. Visit megaphone.fm/adchoices -
Mangler du episoder?
-
As the UK transforms its ecosystem for clinical trials, the regulatory landscape is undergoing its biggest change in 20 years. In this third episode of this free New Scientist podcast, we meet Dr Melanie Ivarsson, from the global biotechnology company Moderna, to find out why she chose the UK for a billion-pound research and development program.
Sponsored by the UK Department for Business and Trade and the Medicines and Healthcare products Regulatory Agency
Hosted on Acast. See acast.com/privacy for more information.
Learn more about your ad choices. Visit megaphone.fm/adchoices -
As the UK transforms its ecosystem for clinical trials, the regulatory landscape is undergoing its biggest change in 20 years. In this free New Scientist podcast, we meet Professor Andrea Manfrin whose team is responsible for driving this change at the Medicines and Healthcare products Regulatory Agency.
Sponsored by the UK Department for Business and Trade and the Medicines and Healthcare products Regulatory Agency
Hosted on Acast. See acast.com/privacy for more information.
Learn more about your ad choices. Visit megaphone.fm/adchoices -
The UK has long been a world leader for clinical trials and life sciences research. But after losing ground post-COVID and post-Brexit, the country has begun to rethink the landscape for clinical trials. In this free New Scientist podcast, we meet the chair of the UK review into commercial clinical trials, James O'Shaughnessy, and ask how the independent review has influenced the reinvention of the clinical trials infrastructure for a new age of medicine.
Sponsored by the UK Department for Business and Trade and the Medicines and Healthcare products Regulatory Agency
Hosted on Acast. See acast.com/privacy for more information.
Learn more about your ad choices. Visit megaphone.fm/adchoices
